These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 21410627

  • 41. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM.
    Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
    [Abstract] [Full Text] [Related]

  • 42. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group.
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [Abstract] [Full Text] [Related]

  • 43. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
    Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, O'Neill EA, Engel SS, Kaufman KD, Makimura H, Crutchlow MF.
    Diabetes Obes Metab; 2019 May; 21(5):1128-1135. PubMed ID: 30609212
    [Abstract] [Full Text] [Related]

  • 44. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z.
    Diabetes Obes Metab; 2015 Sep; 17(9):849-58. PubMed ID: 25912221
    [Abstract] [Full Text] [Related]

  • 45. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E, Dotta F, Jia Y, Goodman M.
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [Abstract] [Full Text] [Related]

  • 46. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
    Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM.
    Diabetes Obes Metab; 2010 Jul; 12(7):613-22. PubMed ID: 20590736
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
    Scott R, Loeys T, Davies MJ, Engel SS, Sitagliptin Study 801 Group.
    Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
    [Abstract] [Full Text] [Related]

  • 50. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
    Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R.
    Diabet Med; 2011 Mar; 28(3):333-7. PubMed ID: 21309842
    [Abstract] [Full Text] [Related]

  • 51. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB, Montanya E, Pratley RE, Blonde L, Svendsen CB, Donsmark M, Sesti G.
    Endocr Pract; 2013 Mar; 19(1):64-72. PubMed ID: 23186975
    [Abstract] [Full Text] [Related]

  • 52. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV, Marcinak JF, Raanan MG, Cao C.
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [Abstract] [Full Text] [Related]

  • 53. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R, Duran-García S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS.
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [Abstract] [Full Text] [Related]

  • 54. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
    Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V, EASIE investigators.
    Lancet; 2012 Jun 16; 379(9833):2262-9. PubMed ID: 22683131
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct 16; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 56. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
    Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B.
    Diabetes Obes Metab; 2018 Mar 16; 20(3):530-540. PubMed ID: 28921862
    [Abstract] [Full Text] [Related]

  • 57. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun 16; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM.
    Drugs; 2011 Feb 12; 71(3):349-61. PubMed ID: 21319871
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.